These results suggest that co-treatment of KRAS mutant-targeting ASOs and RIG-I agonist RNA using the RBCEV platform may enhance immune cell infiltration and potentially promote a more immunologically active tumor microenvironment. Here, RIGI is linked to neoplasm.